US20020164644A1 - Adsorbents for high mobility group proteins and column for purifying body fluid - Google Patents
Adsorbents for high mobility group proteins and column for purifying body fluid Download PDFInfo
- Publication number
- US20020164644A1 US20020164644A1 US09/980,624 US98062402A US2002164644A1 US 20020164644 A1 US20020164644 A1 US 20020164644A1 US 98062402 A US98062402 A US 98062402A US 2002164644 A1 US2002164644 A1 US 2002164644A1
- Authority
- US
- United States
- Prior art keywords
- group
- adsorbent
- body fluid
- functional group
- adsorbent according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003463 adsorbent Substances 0.000 title claims abstract description 67
- 102000018802 High Mobility Group Proteins Human genes 0.000 title claims abstract description 41
- 108010052512 High Mobility Group Proteins Proteins 0.000 title claims abstract description 41
- 210000001124 body fluid Anatomy 0.000 title claims abstract description 19
- 239000010839 body fluid Substances 0.000 title claims abstract description 19
- 125000000524 functional group Chemical group 0.000 claims abstract description 51
- 239000000126 substance Substances 0.000 claims abstract description 22
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 10
- 238000001179 sorption measurement Methods 0.000 claims description 42
- 239000000835 fiber Substances 0.000 claims description 20
- 239000011324 bead Substances 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 9
- 206010040047 Sepsis Diseases 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 238000000746 purification Methods 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 125000002091 cationic group Chemical group 0.000 claims description 8
- 229920000669 heparin Polymers 0.000 claims description 7
- 229960002897 heparin Drugs 0.000 claims description 7
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 7
- 125000000129 anionic group Chemical group 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 5
- 229960000633 dextran sulfate Drugs 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 4
- 125000000542 sulfonic acid group Chemical group 0.000 claims description 4
- 102000007562 Serum Albumin Human genes 0.000 claims description 3
- 108010071390 Serum Albumin Proteins 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 2
- 108010039918 Polylysine Proteins 0.000 claims description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 2
- 229920000656 polylysine Polymers 0.000 claims description 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 claims description 2
- 125000001302 tertiary amino group Chemical group 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims 1
- 101100422412 Catharanthus roseus SSRP1 gene Proteins 0.000 abstract description 13
- 101150004167 HMG gene Proteins 0.000 abstract description 13
- 102100037907 High mobility group protein B1 Human genes 0.000 description 25
- 101710168537 High mobility group protein B1 Proteins 0.000 description 25
- 102000009027 Albumins Human genes 0.000 description 13
- 108010088751 Albumins Proteins 0.000 description 13
- 229920000936 Agarose Polymers 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- -1 DNAs and RNAs Chemical class 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 101001025320 Bos taurus High mobility group protein B1 Proteins 0.000 description 4
- 102000055207 HMGB1 Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 102100022128 High mobility group protein B2 Human genes 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical group NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 235000010724 Wisteria floribunda Nutrition 0.000 description 2
- 0 [1*][N+]([2*])([3*])C Chemical compound [1*][N+]([2*])([3*])C 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000012510 hollow fiber Substances 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- LSZVFTBAMCUSBG-UHFFFAOYSA-N 3-(iminomethylideneamino)-1-n,1-n'-dimethylpentane-1,1-diamine;hydrochloride Chemical compound Cl.N=C=NC(CC)CC(NC)NC LSZVFTBAMCUSBG-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000049983 HMGA1a Human genes 0.000 description 1
- 108700010012 HMGN1 Proteins 0.000 description 1
- 108700010011 HMGN2 Proteins 0.000 description 1
- 102000055206 HMGN2 Human genes 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 101710168540 High mobility group protein B2 Proteins 0.000 description 1
- 101710187036 High mobility group protein HMG-I/HMG-Y Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101001045791 Homo sapiens High mobility group protein B2 Proteins 0.000 description 1
- 101000866795 Homo sapiens Non-histone chromosomal protein HMG-14 Proteins 0.000 description 1
- 101000866805 Homo sapiens Non-histone chromosomal protein HMG-17 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100031353 Non-histone chromosomal protein HMG-14 Human genes 0.000 description 1
- 102100031346 Non-histone chromosomal protein HMG-17 Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- UMGDCJDMYOKAJW-UHFFFAOYSA-N aminothiocarboxamide Natural products NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000004202 carbamide Chemical group 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 238000006068 polycondensation reaction Methods 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/26—Synthetic macromolecular compounds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/26—Synthetic macromolecular compounds
- B01J20/261—Synthetic macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/26—Synthetic macromolecular compounds
- B01J20/262—Synthetic macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. obtained by polycondensation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/26—Synthetic macromolecular compounds
- B01J20/265—Synthetic macromolecular compounds modified or post-treated polymers
- B01J20/267—Cross-linked polymers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28014—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their form
- B01J20/28016—Particle form
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28014—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their form
- B01J20/28023—Fibres or filaments
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3206—Organic carriers, supports or substrates
- B01J20/3208—Polymeric carriers, supports or substrates
- B01J20/321—Polymeric carriers, supports or substrates consisting of a polymer obtained by reactions involving only carbon to carbon unsaturated bonds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3206—Organic carriers, supports or substrates
- B01J20/3208—Polymeric carriers, supports or substrates
- B01J20/3212—Polymeric carriers, supports or substrates consisting of a polymer obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3214—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the method for obtaining this coating or impregnating
- B01J20/3217—Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3214—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the method for obtaining this coating or impregnating
- B01J20/3217—Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond
- B01J20/3219—Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond involving a particular spacer or linking group, e.g. for attaching an active group
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3214—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the method for obtaining this coating or impregnating
- B01J20/3225—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the method for obtaining this coating or impregnating involving a post-treatment of the coated or impregnated product
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3244—Non-macromolecular compounds
- B01J20/3246—Non-macromolecular compounds having a well defined chemical structure
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3244—Non-macromolecular compounds
- B01J20/3246—Non-macromolecular compounds having a well defined chemical structure
- B01J20/3248—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3244—Non-macromolecular compounds
- B01J20/3246—Non-macromolecular compounds having a well defined chemical structure
- B01J20/3248—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such
- B01J20/3251—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such comprising at least two different types of heteroatoms selected from nitrogen, oxygen or sulphur
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3268—Macromolecular compounds
- B01J20/3272—Polymers obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
- B01J20/3274—Proteins, nucleic acids, polysaccharides, antibodies or antigens
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/16—Organic material
- B01J39/17—Organic material containing also inorganic materials, e.g. inert material coated with an ion-exchange resin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/16—Organic material
- B01J39/18—Macromolecular compounds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J41/00—Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
- B01J41/08—Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
- B01J41/10—Inorganic material
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J41/00—Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
- B01J41/08—Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
- B01J41/12—Macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2220/00—Aspects relating to sorbent materials
- B01J2220/50—Aspects relating to the use of sorbent or filter aid materials
- B01J2220/58—Use in a single column
Definitions
- the present invention relates to an adsorbent for adsorbing high-mobility-group proteins (hereinafter also referred to as “HMG proteins” for short).
- HMG proteins high-mobility-group proteins
- the present invention is suitably used for improving the state of sepsis by removing HMG proteins in human blood.
- HMG proteins are a group of non-histone DNA-binding proteins, and HMG-1, HMG2, HMG14, HMG17, HMG I(Y) and the like are known. HMG have been thought to participate in acceleration of transcription and growth of cells by binding to DNA in the cells. It was proved that amphoterin discovered as a factor which exists on the surface of nerve cells and extends dendrite is HMG-1 that is one of HMG proteins, so that it is suggested that HMG proteins exhibit a wide variety of actions.
- HMG-1 is secreted to the outside of the cells and acts as a strong mediator of systemic inflammation reaction and septic shock (Wang et al., (1999), Science vol.285, p248). That is, if lipopolysaccharide (LPS) is administered to a mouse, HMG-1 level in the serum is drastically increased at 8 to 24 hours after administration and the mouse dies. In case of administering purified HMG-1 together with LPS, these synergistically act and show lethal activity, and the lethal action by LPS is inhibited by administering an anti-HMG-1 antibody, so that it was shown that HMG-1 is an important mediator of endotoxin shock.
- LPS lipopolysaccharide
- HMG-1 level is drastically increased, especially where the patient dies. HMG-1 level in blood is also increased in hemorrhagic shock (Ombrellino et al., (1999), Lancet vol.354, p1446). Further, it has been reported that production of HMG-I(Y) belonging to HMG-1 is induced by stimulation with LPS.
- HMG proteins participate in these inflammatory diseases (Sobajima et al., (1997), Clin. Exp. Immunol. vol. 107, p135). Further, it has been reported that HMG proteins participate in growth of cancers (Taguchi et al., (2000), Nature vol.405, p354).
- HMG proteins have functions which are necessary to the body, in diseases such as sepsis, they are secreted in excess to the outside of the cells to make the disease worse and to make the body die.
- a candidate of the method for improving the state of the diseases caused by HMG proteins is to administer a drug such as an antibody, which binds to HMG and inhibits its action.
- a drug inhibiting HMG activity may cause a serious side effects.
- an object of the present invention is to provide an adsorbent of HMG proteins which can effectively remove HMG proteins in body fluid.
- the present inventors intensively studied to discover that by immobilizing a substance having a particular functional group, the HMG proteins in body fluid can be effectively removed, thereby completing the present invention.
- the present invention provides an adsorbent of high-mobility-group proteins comprising a water-insoluble carrier on which (a) substance(s) having (a) hydrogen-bondable functional group(s) and/or (a) hydrophobic functional group(s) is(are) immobilized.
- the present invention also provides a body fluid-purification column for removing high-mobility-group proteins, comprising a column, and the adsorbent according to the present invention.
- the present invention further provides a method for adsorbing high-mobility-group proteins in body fluid, comprising contacting the adsorbent according to the present invention with body fluid so as to adsorb the high-mobility-group proteins in the body fluid to the adsorbent.
- the present invention further provides a use of the adsorbent according to the present invention for production of adsorbent material for adsorbing high-mobility-group proteins in body fluid.
- the HMG proteins in the body fluid are effectively adsorbed by the adsorbent so as to eliminate HMG proteins from the body fluid, so that the extracellular HMG proteins which are undesirable to the body may be removed.
- the adsorbent of HMG proteins according to the present invention comprises an adsorbent of high-mobility-group proteins comprising a water-insoluble carrier on which (a) substance(s) having (a) hydrogen-bondable functional group(s) and/or (a) hydrophobic functional group(s) is(are) immobilized.
- Examples of the hydrogen-bondable functional group include cationic functional groups such as primary amino group, secondary amino group, tertiary amino group, imino group and quaternary ammonium group; anionic functional groups such as carboxyl group, sulfate groups, sulfonic acid group and phosphate group; and functional groups and structures having large polarity such as hydroxyl group, thiol group, aldehyde group, carbonyl group, urea bond and thiourea bond.
- cationic functional groups such as primary amino group, secondary amino group, tertiary amino group, imino group and quaternary ammonium group
- anionic functional groups such as carboxyl group, sulfate groups, sulfonic acid group and phosphate group
- functional groups and structures having large polarity such as hydroxyl group, thiol group, aldehyde group, carbonyl group, urea bond and thiourea bond.
- cationic functional groups and anionic functional groups are preferred.
- amino groups and quaternary ammonium group are especially preferred.
- examples of the especially preferred amino groups and quaternary ammonium group include those represented by the following Formula (I):
- R 1 , R 2 and R 3 independently represent hydrogen atom or a C 1 -C 5 alkyl group, respectively
- alkyl group includes both linear and branched alkyl groups.
- R 1 , R 2 and R 3 independently represent hydrogen atom or a C 1 -C 2 alkyl group, respectively, are more preferred, and those wherein all of R 1 , R 2 and R 3 represent methyl group are still more preferred.
- the functional groups may be employed individually or in combination.
- anionic functional groups among those described above, carboxyl group, sulfate groups and sulfonic acid group are especially preferred. These functional groups may be employed individually or in combination.
- hydrophobic functional groups alkyl groups having not less than 6 carbon atoms, and aromatic groups are preferred. Although there is no specific upper limit of the number of carbon atoms in the alkyl group, it is usually about 30.
- aromatic groups include phenyl group, naphthyl group, and arylalkyl group and aralkyl group in which phenyl group or naphthyl group is substituted with one or more alkyl groups (preferably the number of carbon atoms in each alkyl group is 1 to 30). These functional groups may be employed individually or in combination.
- the substance which is to be immobilized on the water-insoluble carrier is not restricted as long as the substance has one or more of the above-mentioned functional groups.
- the substance include low molecular synthetic compounds; synthetic polymers; naturally occurring low molecular compounds such as amino acids and sugars; saccharides such as oligo saccharides and polysaccharides, and derivatives thereof; peptides, proteins and modified products thereof; nucleic acids such as DNAs and RNAs, and derivatives thereof; and other physiologically active substances, biopolymers and compounds originated from microorganisms.
- those having molecular weights of not more than 20,000 are preferred, and those having molecular weights of not more than 5000 are more preferred. Especially, those having molecular weights of about 50 to 500 are preferred.
- Preferred examples of the above-mentioned substances having cationic functional groups include amino acids such as lysine and arginine, and peptides consisting of, or containing a large amount of (preferably not less than 30 mol %) these amino acids, for example, polylysine.
- Examples of the substances having anionic functional groups include heparin and dextran sulfate which are sulfated polysaccharides containing a number of sulfate groups, as well as derivatives thereof. Since what is necessary is the sulfate group, the term “derivative” includes any derivatives which retain the sulfate groups of the heparin or dextran sulfate.
- Examples of the preferred substances having carboxyl group or sulfonic acid group include amino acids such as aspartic acid and glutamic acid, and peptides consisting of, or containing a large amount of (preferably not less than 30 mol %) these amino acids.
- Preferred examples of the substances having hydrophobic functional groups include hydrophobic amino acids such as phenylalanine and tryptophan, and peptides consisting of, or containing a large amount of (preferably not less than 30 mol %) these amino acids.
- the density of the above-mentioned functional groups is not restricted, the number of the above-mentioned functional groups (in cases where a plurality of kinds of functional groups are contained, the total thereof per 1 g dry weight of the water-insoluble carrier on which the functional groups are immobilized is preferably about 1 ⁇ mol to 1 mmol, more preferably about 10 ⁇ mol to 1 mmol.
- a material comprising a water-insoluble carrier and (an) antibody(ies) to HMG protein may also be used as the adsorbent of the HMG protein.
- the materials which may suitably be used as the water-insoluble carrier used in the present invention include synthetic polymers such as polyamides, polyimides, poly(aromatic vinyl compounds), polyesters, polymethylmethacrylates, polysulfones, polyethylenes, polyvinylalcohols and polytetrafluoroethylenes; and naturally occurring polymers such as cellulose, collagen, chitin, chitosan and dextran, as well as derivatives thereof.
- inorganic materials such as metals, ceramics and glass, of which surfaces are covered with an appropriate polymer, and of which surfaces are directly modified may also be suitably employed.
- the material used in the present invention may be in the form of fibers, hollow fibers, beads, flat membrane, or powder.
- porous materials having large contacting area are preferred.
- the beads since those giving small pressure loss when being packed in a column, and since those having large surface area are preferred, those having particle sizes of 50 to 1000 ⁇ m, especially 200 to 700 ⁇ m, are preferred.
- the adsorbent according to the present invention may preferably be one which selectively adsorb HMG protein such that, when the above-mentioned adsorbent of the present invention is subjected to adsorption treatment of HGM-containing serum, the rate of adsorption of the HMG protein is not less than 50%, preferably not less than 80%, still more preferably not less than 90%, still more preferably not less than 95%, and the rate of adsorption of albumin in serum is not more than 20%, preferably not more than 15%, and still more preferably not more than 10%.
- Such an adsorbent which selectively adsorb HMG protein may be obtained by immobilizing the above-mentioned preferred functional groups on the water-insoluble carrier at the above-mentioned preferred density, and a plurality of concrete examples are described in the Examples below.
- rate of adsorption of HMG protein or albumin means what percent of bovine HMG-1 protein in the sample solution is adsorbed, or what percent of serum albumin in the sample solution is adsorbed, when 50 ⁇ l of the adsorbent is added to 0.4 ml of sample solution prepared by adding bovine HMG-1 protein to normal human serum to a concentration of 600 ng/ml, and then shaking the resulting mixture at 37° C. for 2 hours.
- Immobilization of the substance having the above-mentioned functional groups on the water-insoluble carrier via covalent bond may be accomplished by known methods such as reaction with the carrier activated with cyanogen bromide, polycondensation by carbodiimide, crosslinkage by a divalent reagent which reacts with amino group or thiol group, and crosslinkage by glutaraldehyde.
- reaction with the carrier activated with cyanogen bromide polycondensation by carbodiimide
- crosslinkage by a divalent reagent which reacts with amino group or thiol group and crosslinkage by glutaraldehyde.
- those wherein the substance containing the above-mentioned functional group(s) is bound to the water-insoluble carrier via covalent bond is also included in “water-insoluble carrier on which the substance is immobilized”.
- those wherein the above-mentioned functional groups are introduced or included from the step of synthesizing the water-insoluble carrier is also included in “water-
- the adsorbent By packing the adsorbent according to the present invention in a column, a body fluid-purification column for removing high-mobility-group proteins is obtained.
- the adsorbent may be packed into the column by making the fibers into woven fabric, knit or non-woven fabric, and by stacking and packing the resulting fabric into the column, or by winding the fabric around a hollow core pipe having pores, and passing the solution from the inside to the outside.
- the adsorbent according to the present invention By packing the adsorbent according to the present invention into a column and by making a body fluid containing HMG proteins such as blood or plasma of a patient pass through the column by extracorporeal circulation, therapy of diseases such as sepsis may be carried out.
- a body fluid containing HMG proteins such as blood or plasma of a patient pass through the column by extracorporeal circulation
- therapy of diseases such as sepsis may be carried out.
- the column according to the present invention together with a body fluid-purification column for adsorbing bacterial components, especially high therapeutic effect against sepsis is expected to be obtained.
- the adsorbent of the present invention may also be suitably used for the therapy of diseases such as cancers and autoimmune diseases.
- Rate of Adsorption [1- ⁇ concentration after adsorption (ng/ml) ⁇ 0.45 (ml) ⁇ / ⁇ concentration before adsorption (ng/ml) ⁇ 0.4 (ml) ⁇ ] ⁇ 100
- Serum albumin levels before and after the reaction were measured by using an automatic blood biochemistry analyzing apparatus (Fuji Drychem 5500 commercially available from Fuji Photo Film Co., Ltd), and the rate of adsorption of albumin was calculated in the same manner as in the calculation of rate of adsorption of HMG-1.
- bovine HMG-1 protein was added to a concentration of 600 ng/ml.
- 50 ⁇ l of crosslinked agarose beads containing one of the following types of functional groups were added, and each of the resulting solution was shaken at 37° C. for 2 hours.
- Adsorbent (1)—N + (CH 3 ) 3 , (2)—N 30 (C 2 H 5 ) 2 H, (3)—SO 3 —, (4)—COO—, (5)—(CH 2 ) 7 —CH 3 , (6)—C 6 H 5
- Each adsorbent was prepared as follows: One gram of crosslinked agarose beads activated with cyanogen bromide were mixed with 10 ml of each physiologically active substance solution with a concentration of 5 mg/ml in 0.1 M aqueous sodium hydrogen carbonate solution containing 0.5 M sodium chloride, and the resulting mixture was allowed to react at 4° C. for 24 hours. Then ethanolamine was added to 0.1 M and the resulting mixture was allowed to react at room temperature for 2 hours, thereby blocking the non-reacted active groups. The obtained beads were washed with distilled water and used in the experiments.
- Each adsorbent was prepared as follows: One gram of crosslinked agarose beads activated with cyanogen bromide were mixed with 10 ml of each amino acid solution with a concentration of 5 mg/ml in 0.1 M aqueous sodium hydrogen carbonate solution containing 0.5 M sodium chloride, and the resulting mixture was allowed to react at 4° C. for 24 hours. Then ethanolamine was added to 0.1 M and the resulting mixture was allowed to react at room temperature for 2 hours, thereby blocking the non-reacted active groups. The obtained beads were washed with distilled water and used in the experiments.
- Sea-island type composite fibers (thickness: 2.6 denier, number of islands: 16) described in U.S. Pat. No. 4,661,260 consisting of 50 parts by weight of sea component (a mixture of 46 parts by weight of polystyrene and 4 parts by weight of polypropylene) and 50 parts by weight of island component (polypropylene) were mixed with 50 g of N-methyrol- ⁇ -chloroacetamide, 400 g of nitrobenzene, 400 g of 98% sulfuric acid and 0.85 g of paraformaldehyde, and the resulting mixture was allowed to react at 20° C. for 1 hour. The fibers were then washed with nitrobenzene and placed in water to stop the reaction. Thereafter, the fibers were again washed with methanol and warm water to obtain chloroacetamide methylated crosslinked polystyrene fibers (hereinafter referred to as “AMPSt fibers” for short).
- AMPSt fibers chloroace
- AMPSt fibers To 300 mg of AMPSt fibers, 8 ml of 1% v/v ethylenediamine solution in 0.1 M sodium hydrogen carbonate solution was added and the mixture was allowed to react at 37° C. for 3 hours, thereby introducing amino groups to the fibers. After washing the obtained aminated fibers, 6 ml of 6.7 mg/ml of aqueous heparin solution and 2 ml of 1-ethyl-3,3-dimethylaminopropylcarbodiimide hydrochloride solution were added and the resulting mixture was allowed to react at room temperature for 21 hours to obtain heparinated fibers. The obtained fibers will be hereinafter referred to as “Adsorbent A”.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- External Artificial Organs (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
An adsorbent of high-mobility-group proteins (HMG protein) which can remove HMG protein in body fluid is disclosed. The adsorbent according to the present invention comprises a water-insoluble carrier on which (a) substance(s) having (a) hydrogen-bondable functional group(s) and/or (a) hydrophobic functional group(s) is(are) immobilized.
Description
- The present invention relates to an adsorbent for adsorbing high-mobility-group proteins (hereinafter also referred to as “HMG proteins” for short). The present invention is suitably used for improving the state of sepsis by removing HMG proteins in human blood.
- HMG proteins are a group of non-histone DNA-binding proteins, and HMG-1, HMG2, HMG14, HMG17, HMG I(Y) and the like are known. HMG have been thought to participate in acceleration of transcription and growth of cells by binding to DNA in the cells. It was proved that amphoterin discovered as a factor which exists on the surface of nerve cells and extends dendrite is HMG-1 that is one of HMG proteins, so that it is suggested that HMG proteins exhibit a wide variety of actions.
- Recently, it was reported that HMG-1 is secreted to the outside of the cells and acts as a strong mediator of systemic inflammation reaction and septic shock (Wang et al., (1999), Science vol.285, p248). That is, if lipopolysaccharide (LPS) is administered to a mouse, HMG-1 level in the serum is drastically increased at 8 to 24 hours after administration and the mouse dies. In case of administering purified HMG-1 together with LPS, these synergistically act and show lethal activity, and the lethal action by LPS is inhibited by administering an anti-HMG-1 antibody, so that it was shown that HMG-1 is an important mediator of endotoxin shock. In patients suffering from sepsis, HMG-1 level is drastically increased, especially where the patient dies. HMG-1 level in blood is also increased in hemorrhagic shock (Ombrellino et al., (1999), Lancet vol.354, p1446). Further, it has been reported that production of HMG-I(Y) belonging to HMG-1 is induced by stimulation with LPS.
- It was observed that in autoimmune hepatitis, inflammatory bowel disease and in systemic rheumatic diseases, autoantibodies to HMG proteins such as HMG-1, HMG-2, HMG-14 and HMG-17 are produced, so that it is suggested that HMG proteins participate in these inflammatory diseases (Sobajima et al., (1997), Clin. Exp. Immunol. vol. 107, p135). Further, it has been reported that HMG proteins participate in growth of cancers (Taguchi et al., (2000), Nature vol.405, p354).
- Thus, although HMG proteins have functions which are necessary to the body, in diseases such as sepsis, they are secreted in excess to the outside of the cells to make the disease worse and to make the body die. A candidate of the method for improving the state of the diseases caused by HMG proteins is to administer a drug such as an antibody, which binds to HMG and inhibits its action. However, in view of the fact that HMG proteins have functions which are necessary in the cells and on the surfaces of the cells, it is concerned that administration of a drug inhibiting HMG activity may cause a serious side effects. Thus, it is desired to provide means for selectively removing extracellular HMG proteins which are undesirable to the body.
- It has been reported that some substances such as heparin and RAGE, in addition to the above-mentioned antibodies, bind to HMG proteins (Hori et al., (1995), J. Biol. Chem. vol. 270, p25752, and so on). However, it has not hitherto been proposed to use these HMG protein-binding substances for removing HMG proteins from the body, and no materials which can remove HMG proteins from body fluids are known.
- Accordingly, an object of the present invention is to provide an adsorbent of HMG proteins which can effectively remove HMG proteins in body fluid.
- The present inventors intensively studied to discover that by immobilizing a substance having a particular functional group, the HMG proteins in body fluid can be effectively removed, thereby completing the present invention.
- That is, the present invention provides an adsorbent of high-mobility-group proteins comprising a water-insoluble carrier on which (a) substance(s) having (a) hydrogen-bondable functional group(s) and/or (a) hydrophobic functional group(s) is(are) immobilized. The present invention also provides a body fluid-purification column for removing high-mobility-group proteins, comprising a column, and the adsorbent according to the present invention. The present invention further provides a method for adsorbing high-mobility-group proteins in body fluid, comprising contacting the adsorbent according to the present invention with body fluid so as to adsorb the high-mobility-group proteins in the body fluid to the adsorbent. The present invention further provides a use of the adsorbent according to the present invention for production of adsorbent material for adsorbing high-mobility-group proteins in body fluid.
- By contacting the adsorbent of the present invention with the body fluid, the HMG proteins in the body fluid are effectively adsorbed by the adsorbent so as to eliminate HMG proteins from the body fluid, so that the extracellular HMG proteins which are undesirable to the body may be removed.
- As described above, the adsorbent of HMG proteins according to the present invention comprises an adsorbent of high-mobility-group proteins comprising a water-insoluble carrier on which (a) substance(s) having (a) hydrogen-bondable functional group(s) and/or (a) hydrophobic functional group(s) is(are) immobilized.
- Examples of the hydrogen-bondable functional group include cationic functional groups such as primary amino group, secondary amino group, tertiary amino group, imino group and quaternary ammonium group; anionic functional groups such as carboxyl group, sulfate groups, sulfonic acid group and phosphate group; and functional groups and structures having large polarity such as hydroxyl group, thiol group, aldehyde group, carbonyl group, urea bond and thiourea bond.
- Among these, cationic functional groups and anionic functional groups are preferred.
-
- (wherein R1, R2 and R3 independently represent hydrogen atom or a C1-C5 alkyl group, respectively)
- It should be noted that in the present specification and in the claims, the term “alkyl group” includes both linear and branched alkyl groups.
- Among the groups represented by Formula (I), those wherein R1, R2 and R3 independently represent hydrogen atom or a C1-C2 alkyl group, respectively, are more preferred, and those wherein all of R1, R2 and R3 represent methyl group are still more preferred. The functional groups may be employed individually or in combination.
- As the anionic functional groups, among those described above, carboxyl group, sulfate groups and sulfonic acid group are especially preferred. These functional groups may be employed individually or in combination.
- As the hydrophobic functional groups, alkyl groups having not less than 6 carbon atoms, and aromatic groups are preferred. Although there is no specific upper limit of the number of carbon atoms in the alkyl group, it is usually about 30. Examples of the aromatic groups include phenyl group, naphthyl group, and arylalkyl group and aralkyl group in which phenyl group or naphthyl group is substituted with one or more alkyl groups (preferably the number of carbon atoms in each alkyl group is 1 to 30). These functional groups may be employed individually or in combination.
- The substance which is to be immobilized on the water-insoluble carrier is not restricted as long as the substance has one or more of the above-mentioned functional groups. Examples of the substance include low molecular synthetic compounds; synthetic polymers; naturally occurring low molecular compounds such as amino acids and sugars; saccharides such as oligo saccharides and polysaccharides, and derivatives thereof; peptides, proteins and modified products thereof; nucleic acids such as DNAs and RNAs, and derivatives thereof; and other physiologically active substances, biopolymers and compounds originated from microorganisms. In view of the stability to sterilization treatment, those having molecular weights of not more than 20,000 are preferred, and those having molecular weights of not more than 5000 are more preferred. Especially, those having molecular weights of about 50 to 500 are preferred.
- Preferred examples of the above-mentioned substances having cationic functional groups include amino acids such as lysine and arginine, and peptides consisting of, or containing a large amount of (preferably not less than 30 mol %) these amino acids, for example, polylysine.
- Examples of the substances having anionic functional groups include heparin and dextran sulfate which are sulfated polysaccharides containing a number of sulfate groups, as well as derivatives thereof. Since what is necessary is the sulfate group, the term “derivative” includes any derivatives which retain the sulfate groups of the heparin or dextran sulfate. Examples of the preferred substances having carboxyl group or sulfonic acid group include amino acids such as aspartic acid and glutamic acid, and peptides consisting of, or containing a large amount of (preferably not less than 30 mol %) these amino acids.
- Preferred examples of the substances having hydrophobic functional groups include hydrophobic amino acids such as phenylalanine and tryptophan, and peptides consisting of, or containing a large amount of (preferably not less than 30 mol %) these amino acids.
- Although the density of the above-mentioned functional groups is not restricted, the number of the above-mentioned functional groups (in cases where a plurality of kinds of functional groups are contained, the total thereof per 1 g dry weight of the water-insoluble carrier on which the functional groups are immobilized is preferably about 1 μmol to 1 mmol, more preferably about 10 μmol to 1 mmol.
- A material comprising a water-insoluble carrier and (an) antibody(ies) to HMG protein may also be used as the adsorbent of the HMG protein. Examples of the materials which may suitably be used as the water-insoluble carrier used in the present invention include synthetic polymers such as polyamides, polyimides, poly(aromatic vinyl compounds), polyesters, polymethylmethacrylates, polysulfones, polyethylenes, polyvinylalcohols and polytetrafluoroethylenes; and naturally occurring polymers such as cellulose, collagen, chitin, chitosan and dextran, as well as derivatives thereof. In addition, inorganic materials such as metals, ceramics and glass, of which surfaces are covered with an appropriate polymer, and of which surfaces are directly modified may also be suitably employed.
- The material used in the present invention may be in the form of fibers, hollow fibers, beads, flat membrane, or powder. Those in the form of fibers, hollow fibers or beads, which are also suited for extracorporeal circulation of whole blood in which blood cells and plasma pass through a column without being separated, are preferred. To increase the rate of adsorption, porous materials having large contacting area are preferred. As the beads, since those giving small pressure loss when being packed in a column, and since those having large surface area are preferred, those having particle sizes of 50 to 1000 μm, especially 200 to 700 μm, are preferred.
- The adsorbent according to the present invention may preferably be one which selectively adsorb HMG protein such that, when the above-mentioned adsorbent of the present invention is subjected to adsorption treatment of HGM-containing serum, the rate of adsorption of the HMG protein is not less than 50%, preferably not less than 80%, still more preferably not less than 90%, still more preferably not less than 95%, and the rate of adsorption of albumin in serum is not more than 20%, preferably not more than 15%, and still more preferably not more than 10%. Such an adsorbent which selectively adsorb HMG protein may be obtained by immobilizing the above-mentioned preferred functional groups on the water-insoluble carrier at the above-mentioned preferred density, and a plurality of concrete examples are described in the Examples below.
- The term “rate of adsorption” of HMG protein or albumin means what percent of bovine HMG-1 protein in the sample solution is adsorbed, or what percent of serum albumin in the sample solution is adsorbed, when 50 μl of the adsorbent is added to 0.4 ml of sample solution prepared by adding bovine HMG-1 protein to normal human serum to a concentration of 600 ng/ml, and then shaking the resulting mixture at 37° C. for 2 hours.
- Immobilization of the substance having the above-mentioned functional groups on the water-insoluble carrier via covalent bond may be accomplished by known methods such as reaction with the carrier activated with cyanogen bromide, polycondensation by carbodiimide, crosslinkage by a divalent reagent which reacts with amino group or thiol group, and crosslinkage by glutaraldehyde. As is apparent from the above description, those wherein the substance containing the above-mentioned functional group(s) is bound to the water-insoluble carrier via covalent bond is also included in “water-insoluble carrier on which the substance is immobilized”. Further, those wherein the above-mentioned functional groups are introduced or included from the step of synthesizing the water-insoluble carrier is also included in “water-insoluble carrier on which the substance is immobilized”.
- By packing the adsorbent according to the present invention in a column, a body fluid-purification column for removing high-mobility-group proteins is obtained. In cases where the adsorbent is in the form of fibers, the adsorbent may be packed into the column by making the fibers into woven fabric, knit or non-woven fabric, and by stacking and packing the resulting fabric into the column, or by winding the fabric around a hollow core pipe having pores, and passing the solution from the inside to the outside.
- By packing the adsorbent according to the present invention into a column and by making a body fluid containing HMG proteins such as blood or plasma of a patient pass through the column by extracorporeal circulation, therapy of diseases such as sepsis may be carried out. By using the column according to the present invention together with a body fluid-purification column for adsorbing bacterial components, especially high therapeutic effect against sepsis is expected to be obtained. Further, the adsorbent of the present invention may also be suitably used for the therapy of diseases such as cancers and autoimmune diseases.
- The present invention will now be described by way of examples thereof.
- (Measuring Method)
- (1) Rate of Adsorption of HMG-1
- The HMG-1 concentrations of a sample before and after the reaction in each Example were determined by ELISA and the rate of adsorption was calculated in Example 4 according to the following equation:
- Rate of Adsorption (%)={1-concentration after adsorption (ng/ml)/concentration before adsorption (ng/ml)}×100
- In Examples 1-3, considering the increase in the volume of the solution by adding an adsorbent with high water content, the rate of adsorption was approximately calculated according to the following equation:
- Rate of Adsorption (%)=[1-{concentration after adsorption (ng/ml)×0.45 (ml)}/{concentration before adsorption (ng/ml)×0.4 (ml)}]×100
- (Note: 0.45=volume (ml) of reaction solution after adsorption, 0.4=volume (ml) of reaction solution before adsorption)
- (2) Rate of Adsorption of Albumin
- Serum albumin levels before and after the reaction were measured by using an automatic blood biochemistry analyzing apparatus (Fuji Drychem 5500 commercially available from Fuji Photo Film Co., Ltd), and the rate of adsorption of albumin was calculated in the same manner as in the calculation of rate of adsorption of HMG-1.
- To normal human serum, bovine HMG-1 protein was added to a concentration of 600 ng/ml. To 0.4 ml of the obtained solution, 50 μl of crosslinked agarose beads containing one of the following types of functional groups were added, and each of the resulting solution was shaken at 37° C. for 2 hours.
- Adsorbent: (1)—N+(CH3)3, (2)—N30(C2H5)2H, (3)—SO3—, (4)—COO—, (5)—(CH2)7—CH3, (6)—C6H5
- As a control, the solution to which the beads were not added was shaken for 2 hours in the same way. The results are shown in Table 1.
- Among the water-insoluble carriers having these functional groups, those having cationic functional groups (1) and (2), and those having anionic functional groups (3) and (4) exhibited adsorption of HMG-1 with high efficiency. The hydrophobic functional groups (5) and (6) also showed adsorption. On the other hand, adsorption of albumin by these adsorbent was small.
TABLE 1 Rate of Adsorption Rate of Adsorption Adsorbent of HMG-1 (%) of Albumin (%) Control 0 0 (1) —N+(CH3)3 99 7 (2) —N+(C2H5)2H 97 17 (3) —SO3 − 97 10 (4) —COO− 88 7 (5) —(CH2)7—CH3 51 15 (6) —C6H5 69 17 - Using the crosslinked beads on which one of the various physiologically active substances shown in Table 2 was immobilized, the adsorption experiments of HMG-1 in normal human serum were carried out in the same manner as in Example 1. As shown in Table 2, the HMG-1 in the serum was adsorbed and removed with high efficiency by (2) heparin, (4) polyL-lysine, (5) dextran sulfate or (7) histamine, and adsorption of albumin which is necessary to the body was small.
- Each adsorbent was prepared as follows: One gram of crosslinked agarose beads activated with cyanogen bromide were mixed with 10 ml of each physiologically active substance solution with a concentration of 5 mg/ml in 0.1 M aqueous sodium hydrogen carbonate solution containing 0.5 M sodium chloride, and the resulting mixture was allowed to react at 4° C. for 24 hours. Then ethanolamine was added to 0.1 M and the resulting mixture was allowed to react at room temperature for 2 hours, thereby blocking the non-reacted active groups. The obtained beads were washed with distilled water and used in the experiments.
TABLE 2 Rate of Adsorption Rate of Adsorption Adsorbent of HMG-1 (%) of Albumin (%) Control 0 0 (1) DNA-agarose 39 13 (2) Heparin-agarose 98 17 (3) Polymixin B-agarose 30 17 (4) Poly-L-lysine-agarose 97 17 (5) Dextran sulfate 91 13 (6) Histamine-agarose 72 10 - Using the crosslinked beads on which one of the various physiologically active substances shown in Table 2 was immobilized, the adsorption experiments of HMG-1 in normal human serum were carried out in the same manner as in Example 1. As shown in Table 3, (2) arginine-immobilized material showed high adsorption, and (1) lysine-immobilized material and (2) tryptophan-immobilized material also showed adsorption. Adsorption of albumin by these materials was small.
- Each adsorbent was prepared as follows: One gram of crosslinked agarose beads activated with cyanogen bromide were mixed with 10 ml of each amino acid solution with a concentration of 5 mg/ml in 0.1 M aqueous sodium hydrogen carbonate solution containing 0.5 M sodium chloride, and the resulting mixture was allowed to react at 4° C. for 24 hours. Then ethanolamine was added to 0.1 M and the resulting mixture was allowed to react at room temperature for 2 hours, thereby blocking the non-reacted active groups. The obtained beads were washed with distilled water and used in the experiments.
TABLE 3 Rate of Adsorption Rate of Adsorption Adsorbent of HMG-1 (%) of Albumin (%) Control 0 0 (1) L-lysine-agarose 52 10 (2) L-arginine-agarose 83 13 (3) L-phenylalanine-agarose 31 13 (4) L-tryptophan-agarose 57 10 - Sea-island type composite fibers (thickness: 2.6 denier, number of islands: 16) described in U.S. Pat. No. 4,661,260 consisting of 50 parts by weight of sea component (a mixture of 46 parts by weight of polystyrene and 4 parts by weight of polypropylene) and 50 parts by weight of island component (polypropylene) were mixed with 50 g of N-methyrol-α-chloroacetamide, 400 g of nitrobenzene, 400 g of 98% sulfuric acid and 0.85 g of paraformaldehyde, and the resulting mixture was allowed to react at 20° C. for 1 hour. The fibers were then washed with nitrobenzene and placed in water to stop the reaction. Thereafter, the fibers were again washed with methanol and warm water to obtain chloroacetamide methylated crosslinked polystyrene fibers (hereinafter referred to as “AMPSt fibers” for short).
- To 300 mg of AMPSt fibers, 8 ml of 1% v/v ethylenediamine solution in 0.1 M sodium hydrogen carbonate solution was added and the mixture was allowed to react at 37° C. for 3 hours, thereby introducing amino groups to the fibers. After washing the obtained aminated fibers, 6 ml of 6.7 mg/ml of aqueous heparin solution and 2 ml of 1-ethyl-3,3-dimethylaminopropylcarbodiimide hydrochloride solution were added and the resulting mixture was allowed to react at room temperature for 21 hours to obtain heparinated fibers. The obtained fibers will be hereinafter referred to as “Adsorbent A”.
- On the other hand, to 300 mg of AMPSt fibers, 8 ml of 1 mg/ml heparin-albumin conjugate preparation (SIGMA) solution in 0.1 M sodium hydrogen carbonate solution (pH 9.6) was added and the mixture was allowed to react at 37° C. for 16 hours. Then the fibers were reacted with Tris-HCl having a final concentration of 0.1 M so as to block the non-reacted active groups to obtain heparin-albumin-bound fibers. The obtained fibers will be hereinafter referred to as “Adsorbent B”.
- To normal human serum, bovine HMG-1 protein was added to a concentration of 600 ng/ml. To 0.4 ml of the obtained solution, 20 mg of Adsorbent A or Adsorbent B obtained by the method described above was added, and each mixture was allowed to react at 37° C. for 2 hours under shaking. The concentrations of HMG-1 and albumin in the serum before and after the reaction were measured and the results are shown in Table 4. It was shown that HMG-1 in the serum is adsorbed and removed by the fibers on which heparin is immobilized. The amount of albumin adsorbed by these materials was small.
TABLE 4 Rate of Adsorption Rate of Adsorption Adsorbent of HMG-1 (%) of Albumin (%) Control 0 0 (1) Adsorbent A 61 15 (2) Adsorbent B 89 10
Claims (30)
1. An adsorbent of high-mobility-group proteins comprising a water-insoluble carrier on which (a) substance(s) having (a) hydrogen-bondable functional group(s) and/or (a) hydrophobic functional group(s) is(are) immobilized.
2. The adsorbent according to claim 1 , wherein said hydrogen-bondable functional group(s) is(are) (a) cationic functional group(s).
3. The adsorbent according to claim 2 , wherein said cationic functional group(s) is(are) primary amino group, secondary amino group, tertiary amino group, imino group and/or quaternary ammonium group.
5. The adsorbent according to claim 4 , wherein in Formula (I), R1, R2 and R3 independently represent hydrogen atom or a C1-C2 alkyl group, respectively.
6. The adsorbent according to claim 5 , wherein all of R1, R2 and R3 in Formula (I) represent methyl group.
7. The adsorbent according to claim 1 , wherein said hydrogen-bondable functional group(s) is(are) (an) anionic functional group(s).
8. The adsorbent according to claim 7 , wherein said hydrogen-bondable functional group(s) is(are) carboxyl group, sulfate group, sulfonic acid group, and/or phosphate group.
9. The adsorbent according to claim 1 , wherein said hydrophobic functional group(s) is(are) (an) alkyl group(s) having not less than 6 carbon atoms, or (an) aromatic group(s).
10. The adsorbent according to claim 1 , wherein said substance(s) having (a) hydrogen-bondable functional group(s) and/or (a) hydrophobic functional group(s) is(are) (a) peptide(s) or (an) amino acid(s).
11. The adsorbent according to claim 3 , wherein said substance(s) having (a) hydrogen-bondable functional group(s) is(are) (a) peptide(s) or (an) amino acid(s) having (an) amino group(s) in its(their) side chain(s).
12. The adsorbent according to claim 11 , wherein said substance having (a) hydrogen-bondable functional group(s) is(are) polylysine.
13. The adsorbent according to claim 7 , wherein (a) polysaccharide(s) having (an) sulfate group(s) is(are) immobilized.
14. The adsorbent according to claim 13 , wherein said polysaccharide is heparin or dextran sulfate, or a derivative thereof.
15. An adsorbent of high-mobility-group proteins comprising a water-insoluble carrier on which (an) antibody(ies) to said high-mobility-group proteins is(are) immobilized.
16. The adsorbent according to claim 15 , wherein said adsorbent has a rate of adsorption for high-mobility-group proteins of not less than 50%, and has a rate of adsorption for serum albumin of not more than 20%.
17. The adsorbent according to any one of claims 1 to 16 , wherein said water-insoluble carrier is in the form of fibers.
18. The adsorbent according to any one of claims 1 to 16 , wherein said water-insoluble carrier is in the form of beads.
19. The adsorbent according to any one of claims 1 to 18 , which is used for therapy of sepsis.
20. A body fluid-purification column for removing high-mobility-group proteins, comprising a column, and said adsorbent according to any one of claims 1 to 19 , which adsorbent is packed in said column.
21. The body fluid-purification column according to claim 20 , by which extracorporeal circulation of whole blood can be attained.
22. The body fluid-purification column according to claim 20 or 21, which is used for therapy of sepsis.
23. A method for adsorbing high-mobility-group proteins in body fluid, comprising contacting said adsorbent according to any one of claims 1 to 18 with body fluid so as to adsorb said high-mobility-group proteins in said body fluid to said adsorbent.
24. The method according to claim 23 , which is carried out by using said body fluid-purification column according to any one of claims 20 to 22 .
25. The method according to claim 23 or 24, wherein said body fluid is blood.
26. The method according to any one of claims 24 to 25 , which is carried out for therapy of sepsis.
27. The method according to claim 26 , which is carried by using said body fluid-purification column according to any one of claims 20 to 22 together with (a) body fluid-purification column(s) which adsorb(s) (a) substance(s) originated from bacteria.
28. Use of said adsorbent according to any one of claims 1 to 18 for production of adsorbent material for adsorbing high-mobility-group proteins in body fluid.
29. The use according to claim 27 , wherein said body fluid is blood.
30. The use according to claim 27 or 28, wherein said adsorbent material is for therapy of sepsis.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/490,095 US7408045B2 (en) | 2000-04-05 | 2006-07-21 | Adsorbent of high-mobility-group protein and body fluid-purification column |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000103328 | 2000-04-05 | ||
JP2000-103328 | 2000-04-05 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/490,095 Division US7408045B2 (en) | 2000-04-05 | 2006-07-21 | Adsorbent of high-mobility-group protein and body fluid-purification column |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020164644A1 true US20020164644A1 (en) | 2002-11-07 |
Family
ID=18617064
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/980,624 Abandoned US20020164644A1 (en) | 2000-04-05 | 2001-04-05 | Adsorbents for high mobility group proteins and column for purifying body fluid |
US11/490,095 Expired - Lifetime US7408045B2 (en) | 2000-04-05 | 2006-07-21 | Adsorbent of high-mobility-group protein and body fluid-purification column |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/490,095 Expired - Lifetime US7408045B2 (en) | 2000-04-05 | 2006-07-21 | Adsorbent of high-mobility-group protein and body fluid-purification column |
Country Status (5)
Country | Link |
---|---|
US (2) | US20020164644A1 (en) |
EP (1) | EP1192963A4 (en) |
JP (1) | JP4945876B2 (en) |
AU (1) | AU783457B2 (en) |
WO (1) | WO2001074420A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004098680A1 (en) | 2003-05-08 | 2004-11-18 | Kaneka Corporation | Low density lipoprotein/fibrinogen adsorbent and adsorption apparatus capable of whole blood treatment |
US20060165647A1 (en) * | 2002-05-30 | 2006-07-27 | Kazuo Teramoto | Immunosuppressive substance adsorbent, extracorporeal cicrulation column and method of treating cancer |
US20070270523A1 (en) * | 2004-11-05 | 2007-11-22 | Kaneka Corporation | Method of Modifying Blood Contact Material and Blood Contact Material Inhibited from Activating Granulocyte |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005115357A2 (en) * | 2004-05-14 | 2005-12-08 | Hans-Dietrich Polaschegg | Taurolidine formulations and delivery |
JP2007029511A (en) * | 2005-07-28 | 2007-02-08 | Kaneka Corp | Adsorbent, adsorption method and adsorber of high mobility group protein |
WO2007069983A1 (en) | 2005-12-13 | 2007-06-21 | Exthera Ab | Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood |
WO2008155683A1 (en) | 2007-06-18 | 2008-12-24 | Firmenich Sa | Malodor counteracting compositions and method for their use |
CN101821252A (en) | 2007-08-29 | 2010-09-01 | 先灵公司 | The indole derivatives and the using method thereof that replace |
JP5374064B2 (en) * | 2008-03-31 | 2013-12-25 | 株式会社カネカ | Method for modifying blood contact material, and blood contact material in which complement activation is suppressed |
CN102740859B (en) | 2009-12-01 | 2016-08-10 | 艾克塞拉医疗公司 | Use and be fixed on the method that the polysaccharide on surface removes cytokine from blood |
JP5824873B2 (en) * | 2010-05-28 | 2015-12-02 | 東レ株式会社 | High mobility group protein adsorption carrier |
WO2012112724A1 (en) | 2011-02-15 | 2012-08-23 | Exthera Medical, Llc | Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines |
ES2647577T3 (en) | 2012-06-13 | 2017-12-22 | Exthera Medical Corporation | Use of heparin and carbohydrates to treat cancer |
EP3620218A1 (en) | 2013-06-24 | 2020-03-11 | ExThera Medical Corporation | Blood filtration system containing mannose coated substrate |
EP3065796B1 (en) | 2013-11-08 | 2020-04-15 | ExThera Medical Corporation | Methods for diagnosing infectious diseases using adsorption media |
CA2946294C (en) | 2014-04-24 | 2023-03-21 | Exthera Medical Corporation | Method for removing bacteria from blood using high flow rate |
AU2015321601B2 (en) | 2014-09-22 | 2020-04-23 | Exthera Medical Corporation | Wearable hemoperfusion device |
US11911551B2 (en) | 2016-03-02 | 2024-02-27 | Exthera Medical Corporation | Method for treating drug intoxication |
WO2017151797A1 (en) | 2016-03-02 | 2017-09-08 | Exthera Medical Corporation | Method for treating drug intoxication |
JP7230478B2 (en) * | 2018-12-13 | 2023-03-01 | 東レ株式会社 | blood purification column |
BR112021021141A2 (en) | 2019-05-16 | 2021-12-14 | Exthera Medical Corp | Method to Modulate Endothelial Glycalyx Structure |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4415665A (en) * | 1980-12-12 | 1983-11-15 | Pharmacia Fine Chemicals Ab | Method of covalently binding biologically active organic substances to polymeric substances |
US4430496A (en) * | 1980-01-17 | 1984-02-07 | Varian Associates, Inc. | Strong anion exchange composition and methods |
US5116962A (en) * | 1985-05-25 | 1992-05-26 | Behringwerke Aktiengesellschaft | Material for affinity chromatography which is a sulfated polysaccharide bonded to an insoluble polymer |
US5773605A (en) * | 1990-04-23 | 1998-06-30 | Akzo Nobel N.V. | Sulfated glycosaminoglycanoid derivatives of the heparin sulfate type |
US6384200B1 (en) * | 1988-06-23 | 2002-05-07 | Associates Of Cape Cod, Inc. | Endotoxin binding and neutralizing protein and uses thereof |
US6608044B1 (en) * | 1998-12-30 | 2003-08-19 | Applied Research Systems Ars Holding N.V. | Inhibition of TNF activity |
US6774102B1 (en) * | 1999-09-29 | 2004-08-10 | Gambro Dialysatoren Gmbh & Co. Kg | Extracorporeal endotoxin removal method |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0738880B2 (en) | 1983-06-24 | 1995-05-01 | 東レ株式会社 | Endotoxemia treatment |
DE3609021A1 (en) * | 1985-03-25 | 1986-09-25 | Bio-Rad Laboratories, Inc., Richmond, Calif. | CHROMATOGRAPHIC SEPARATION MEDIUM FOR FAST ANALYSIS OF SMALL SAMPLES |
JPS62166897A (en) * | 1986-01-20 | 1987-07-23 | Toyo Soda Mfg Co Ltd | Monoclonal antibody against intranuclear nonhistone protein |
CA1327963C (en) * | 1987-09-08 | 1994-03-22 | Ryuichi Yokohari | Autoantibody adsorbent and apparatus for removing autoantibodies using the same |
JPH0622632B2 (en) * | 1987-09-08 | 1994-03-30 | 鐘淵化学工業株式会社 | Adsorbent and removal device |
EP0476721B1 (en) * | 1987-11-20 | 1995-03-01 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | A method for removing serum amyloid protein |
WO1991004086A1 (en) * | 1989-09-18 | 1991-04-04 | Cuno, Incorporated | Filter media and use for pyrogen removal |
US5202029A (en) * | 1991-03-13 | 1993-04-13 | Caron Kabushiki Kaisha | Process for purification of hmg-coa reductase inhibitors |
LT3300B (en) * | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
JP2643823B2 (en) * | 1993-03-25 | 1997-08-20 | 有限会社 エンゼル総合研究所 | Adsorption material and method for producing the same |
EP0810027B1 (en) * | 1995-02-16 | 2002-06-05 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Adsorbent for tumor necrosis factor alpha, method of removal by adsorption, and adsorption device using said adsorbent |
JP3018313B2 (en) * | 1996-02-23 | 2000-03-13 | 雪印乳業株式会社 | Bone formation promotion and bone resorption inhibitor |
IT1299583B1 (en) * | 1998-05-19 | 2000-03-16 | Vander Way Limited | USE OF HMG-I PROTEIN FOR THE PREPARATION OF MEDICATIONS WITH CYTOTOXIC ACTIVITY |
EP1057529A4 (en) * | 1998-12-22 | 2004-08-25 | Toray Industries | Materials for removing bacterial components |
ATE428495T1 (en) * | 1999-04-28 | 2009-05-15 | Toray Industries | MATERIALS FOR REMOVING CANNABINOIDS AND COLUMNS WITH THESE MATERIALS FOR REMOVING CANNABINOIDS |
EP1219639A4 (en) * | 1999-09-08 | 2009-03-25 | Toray Industries | Materials for extracorporeal circulation, adsorbents for diabetic complication factors, containers for eliminating diabetic complication factors and method of eliminating diabetic complication factors |
-
2001
- 2001-04-05 US US09/980,624 patent/US20020164644A1/en not_active Abandoned
- 2001-04-05 EP EP01917826A patent/EP1192963A4/en not_active Ceased
- 2001-04-05 JP JP2001572160A patent/JP4945876B2/en not_active Expired - Fee Related
- 2001-04-05 AU AU44725/01A patent/AU783457B2/en not_active Expired
- 2001-04-05 WO PCT/JP2001/002936 patent/WO2001074420A1/en active IP Right Grant
-
2006
- 2006-07-21 US US11/490,095 patent/US7408045B2/en not_active Expired - Lifetime
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4430496A (en) * | 1980-01-17 | 1984-02-07 | Varian Associates, Inc. | Strong anion exchange composition and methods |
US4415665A (en) * | 1980-12-12 | 1983-11-15 | Pharmacia Fine Chemicals Ab | Method of covalently binding biologically active organic substances to polymeric substances |
US5116962A (en) * | 1985-05-25 | 1992-05-26 | Behringwerke Aktiengesellschaft | Material for affinity chromatography which is a sulfated polysaccharide bonded to an insoluble polymer |
US6384200B1 (en) * | 1988-06-23 | 2002-05-07 | Associates Of Cape Cod, Inc. | Endotoxin binding and neutralizing protein and uses thereof |
US5773605A (en) * | 1990-04-23 | 1998-06-30 | Akzo Nobel N.V. | Sulfated glycosaminoglycanoid derivatives of the heparin sulfate type |
US6608044B1 (en) * | 1998-12-30 | 2003-08-19 | Applied Research Systems Ars Holding N.V. | Inhibition of TNF activity |
US6774102B1 (en) * | 1999-09-29 | 2004-08-10 | Gambro Dialysatoren Gmbh & Co. Kg | Extracorporeal endotoxin removal method |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060165647A1 (en) * | 2002-05-30 | 2006-07-27 | Kazuo Teramoto | Immunosuppressive substance adsorbent, extracorporeal cicrulation column and method of treating cancer |
US8932590B2 (en) | 2002-05-30 | 2015-01-13 | Toray Industries, Inc. | Method of adsorbing transforming growth factor β |
WO2004098680A1 (en) | 2003-05-08 | 2004-11-18 | Kaneka Corporation | Low density lipoprotein/fibrinogen adsorbent and adsorption apparatus capable of whole blood treatment |
EP1621220A1 (en) * | 2003-05-08 | 2006-02-01 | Kaneka Corporation | Low density lipoprotein/fibrinogen adsorbent and adsorption apparatus capable of whole blood treatment |
US20060089587A1 (en) * | 2003-05-08 | 2006-04-27 | Masaru Nakatani | Low density lipoprotein/fibrinogen adsorbent and adsorption apparatus capable of whole blood treatment |
EP1621220A4 (en) * | 2003-05-08 | 2011-10-26 | Kaneka Corp | Low density lipoprotein/fibrinogen adsorbent and adsorption apparatus capable of whole blood treatment |
US20070270523A1 (en) * | 2004-11-05 | 2007-11-22 | Kaneka Corporation | Method of Modifying Blood Contact Material and Blood Contact Material Inhibited from Activating Granulocyte |
Also Published As
Publication number | Publication date |
---|---|
AU4472501A (en) | 2001-10-15 |
AU783457B2 (en) | 2005-10-27 |
JP4945876B2 (en) | 2012-06-06 |
US7408045B2 (en) | 2008-08-05 |
EP1192963A1 (en) | 2002-04-03 |
US20060258853A1 (en) | 2006-11-16 |
WO2001074420A1 (en) | 2001-10-11 |
EP1192963A4 (en) | 2004-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7408045B2 (en) | Adsorbent of high-mobility-group protein and body fluid-purification column | |
US6774102B1 (en) | Extracorporeal endotoxin removal method | |
US6037458A (en) | Adsorbent for serum amyloid protein | |
DE60319702T2 (en) | POLYMEREFFINITY MATRIX, PROCESS FOR THEIR PREPARATION AND USE | |
KR930000269B1 (en) | Membrane and Separation Method | |
RU2167705C2 (en) | Patient-specific immunoadsorbent for extracorporeal apheresis and method of preparation thereof | |
EP0679436A1 (en) | Material for removing HIV and its related substances | |
JPH03238004A (en) | Separation method and separation agent | |
JP3897985B2 (en) | Manufacture of an adsorption device using an adsorbent for reducing the concentration of fibrinogen and / or fibrin | |
JPH0518625B2 (en) | ||
EP1507563B1 (en) | Endotoxin-binding ligands and their use | |
JP3926573B2 (en) | Adsorbent manufacturing method for reducing the concentration of fibrinogen and / or fibrin, adsorbent and use of the adsorbent for the manufacture of an adsorber | |
RU2641924C1 (en) | Sorption material, method of its production and method of its application | |
JP3176753B2 (en) | Adsorbent for blood processing | |
AU2005200745A1 (en) | Adsorbent of high-mobility-group protein and body fluid-purification column | |
JPH01181875A (en) | Adsorptive body of immune complex and removing device for immune complex with it | |
JPS6087854A (en) | Adsorbent for purifying blood | |
JP3157026B2 (en) | Adsorbent for blood purification | |
CN109627334A (en) | Nano antibody, adsorbent using nano antibody as ligand and application of adsorbent | |
JPH0771632B2 (en) | Adsorbent and removal device using the same | |
JPH06237996A (en) | Blood purifying/adsorbing material | |
JP2011139806A (en) | Basic biological substance and body fluid purification device utilizing the derivative thereof | |
JPH06233815A (en) | Hemocatharsis adsorbent | |
WO2013015738A1 (en) | Capture of pathogenic and non-pathogenic biopolymers and bioparticles | |
Ayhan et al. | Protein A immobilized poly (methylmethacrylate-co-hydroxyethylmethacrylate) microbeads for IgG adsorption |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: TORAY INDUSTRIES, INC., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MARUYAMA, IKURO;IDA, NOBUO;MASUKO, SANAE;REEL/FRAME:012738/0836;SIGNING DATES FROM 20020206 TO 20020212 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |